Oridonin (NSC-250682)

For research use only.

Catalog No.S2335 Synonyms: Isodonol, Rubescenin

15 publications

Oridonin (NSC-250682) Chemical Structure

CAS No. 28957-04-2

Oridonin (Isodonol, Rubescenin, NSC-250682), a diterpenoid purified from Rabdosia rubescens, is a traditional agent with antitumor, anti-bacterial and anti-inflammatory effects. Oridonin inhibits AKT1 and AKT2 kinase activity with IC50 of 8.4 μM and 8.9 μM, respectively.

Selleck's Oridonin (NSC-250682) has been cited by 15 publications

1 Customer Review

  • Histopathological analysis of H460 tumors following combination treatment with oridonin and radiation. Hematoxylin and eosin (H-E) staining and immunohistochemistry for cleaved caspase-3 and γ-H2AX were performed on tumors harvested at 14 days after IR. Representative images of H-E-stained tumors (upper images) and cleaved caspase-3- and γ-H2AX-positive cells (middle images, brown staining) and quantification of cleaved caspase-3 and γ-H2AX-positive staining with six mice in each group (lower plots, means ± SEM) are shown; * p < 0.05.

    Int J Mol Sci, 2018, 19(8). Oridonin (NSC-250682) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Oridonin (Isodonol, Rubescenin, NSC-250682), a diterpenoid purified from Rabdosia rubescens, is a traditional agent with antitumor, anti-bacterial and anti-inflammatory effects. Oridonin inhibits AKT1 and AKT2 kinase activity with IC50 of 8.4 μM and 8.9 μM, respectively.
Targets
Akt1 [5]
(Cell-free assay)
Akt2 [5]
(Cell-free assay)
8.4 μM 8.9 μM
In vitro

Oridonin effectively inhibites the proliferation of a wide variety of cancer cells including those from prostate (LNCaP, DU145, PC3), breast (MCF-7, MDA-MB231), non-small cell lung (NSCL) (NCI-H520, NCI-H460, NCI-H1299) cancers, acute promyelocytic leukemia (NB4), and glioblastoma multiforme (U118, U138) with ED50s ranging from 1.8 to 7.5 μg/ml. [1] The antitumor activities of Oridonin may due to its inhibitory effects on NF-kappaB and MAPKs signal pathways. [2] [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 MXrDfZRwfG:6aXPpeJkh[XO|YYm= MXW0PEBpenN? NFrx[FdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9Nk42|ryP Mm\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MUm4O|EoRjJ|OEG5PFcyRC:jPh?=
RAW264.7 Mo\tRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? NHjWbYsyQCCqcoO= NGDiOGRCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25iYX\0[ZIhOThiaILzJIJ6KEe{aXXzd{Bu\XSqb3SsJGlEPTB;NT6y{txO M{jx[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEG5PFcyLz5{M{ixPVg4OTxxYU6=
K562 NWK3VlluSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYO3NkBpenN? MlHvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PC5|M988US=> NWHnSJNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOlU4OzhpPkK4NVY2PzN6PD;hQi=>
Bel7402 M1\4VmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1TnelczKGi{cx?= NIXudVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLlcFc1ODJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21MlQy|ryP M1[5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MU[1O|M5Lz5{OEG2OVc{QDxxYU6=
MGC803 MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3rmRVczKGi{cx?= M3LUe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVfDPFA{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT6wOu69VQ>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF4NUezPEc,OjhzNkW3N|g9N2F-
KB/CP4 NV:4PVVNSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1jSc|Q5KGi{cx?= NGDLSpZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCM2NRPCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGwMljPxE1? NITU[Gk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG2OVc{QCd-MkixOlU4Ozh:L3G+
KB-3-1 MmP3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1rIZlQ5KGi{cx?= M3e2S2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KtN{0yKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUOuNlTPxE1? NGnodZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG2OVc{QCd-MkixOlU4Ozh:L3G+
BEL7404/CP20 MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M1jLUVQ5KGi{cx?= NH7tW|VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLFUFc1ODRxQ2CyNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTF5LkG3{txO NWDNdZNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOlU4OzhpPkK4NVY2PzN6PD;hQi=>
MCF7 MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NEHFfIg4OiCqcoO= MnvsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OTdwOEpOwG0> NULkWFFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOlU4OzhpPkK4NVY2PzN6PD;hQi=>
Bel7404 MmHFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MVS0PEBpenN? MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKnbEe0NFQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zNz65Nu69VQ>? MnjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNkW3N|goRjJ6MU[1O|M5RC:jPh?=
NCI-H460 MnS5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MXq0PEBpenN? MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkCuOVHPxE1? NYjWbHF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOlU4OzhpPkK4NVY2PzN6PD;hQi=>
NCI-H460/MX20 MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NGHRc441QCCqcoO= MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxN02[MkCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zPS56Nt88US=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF4NUezPEc,OjhzNkW3N|g9N2F-
K562 NEn4eYtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NHS0R3o4OiCqcoO= M3\qXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20MlY1|ryP M3TUd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUKxO|U4Lz5|MEmyNVc2PzxxYU6=
SGC7901 M13uUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NFXvOG04OiCqcoO= NXjYemhUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTS2M4QTBzIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTdwMUROwG0> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl{MUe1O{c,OzB7MkG3OVc9N2F-
Bel7402 NI\qVlZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MkTKO|IhcHK| MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKnbEe0NFIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{45Pc7:TR?= M3r6PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUKxO|U4Lz5|MEmyNVc2PzxxYU6=
HL60 MlW4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Ml3kO|IhcHK| M3TObmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25MlQ3|ryP NWOxc4l1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NlE4PTdpPkOwPVIyPzV5PD;hQi=>
PC3 M33qUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M33ZWFczKGi{cx?= NInnbY9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xNE4xP87:TR?= MlrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MkG3OVcoRjNyOUKxO|U4RC:jPh?=
A549 NV3PWnBGSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MV63NkBpenN? MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUiuNVXPxE1? NWHFVpE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NlE4PTdpPkOwPVIyPzV5PD;hQi=>
L02 NFfTSWdEgXSxdH;4bYNqfHliYYPzZZk> MWW3NkBpenN? MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMNFIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVkvPTQQvF2= MoP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MkG3OVcoRjNyOUKxO|U4RC:jPh?=
HCT116 Mkj3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M13J[|Q5KGi{cx?= NX2wVnBmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF03Njh2zszN M1:3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
L02 NUe3TnZyS3m2b4TvfIlkcXS7IHHzd4F6 MoT2OFghcHK| NY\oZXJqS3m2b4TvfIlkcXS7IHnuJIh2dWGwIFywNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[uPVfPxE1? MlmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7OEGxNVMoRjNyOUixNVE{RC:jPh?=
Bel7402 NG\mUnVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MWK0PEBpenN? Mlv0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9PU42Qc7:TR?= M1niWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
MCF7 M1nxUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3L4fFQ5KGi{cx?= NXnyfJRHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVcvPTcQvF2= M2jNdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
MDA-MB-231 NFX2b5FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3T4XVQ5KGi{cx?= NXX3fIZRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiRVO1NF0zQS52zszN NGT1c209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4NVEyOyd-M{C5PFEyOTN:L3G+
HCT116 MYHD[YxtKGO7Y3zlJIFzemW|dDDhd5NigQ>? M2LEcFMhfU1? MlqyNlQhcHK| Mlm2TY5lfWO2aX;uJIlvKGOnbHygZ5lkdGViYYLy[ZN1KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKGmwIHP5Z4xqdiCDIIDyc5RmcW5iZYjwdoV{e2mxbjDs[ZZmdCCjdDCzJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NEOwV|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4NVEyOyd-M{C5PFEyOTN:L3G+
HCT116 M1XkfGNmdGxiY4njcIUh[XK{ZYP0JIF{e2G7 NXXZNo1SOyC3TR?= NUfTT5FOOjRiaILz MkjNTY5lfWO2aX;uJIlvKGOnbHygZ5lkdGViYYLy[ZN1KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKGmwIHP5Z4xqdiCEMTDwdo91\WmwIHX4dJJme3Orb36gcIV3\WxiYYSgN{B2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M2jSWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixNVE{Lz5|MEm4NVEyOzxxYU6=
HCT116 NGHPUXRCeG:ydH;0bYMh[XO|YYm= NHnMWZEyKHWP MlrxNlQhcHK| NGHEN|FKdmS3Y4Tpc44hd2ZiYYDvdJRwfGmlIH3vdpBpd2yxZ3njZYwh[2ijbnflJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDsc5N{KG:oIH;ybYdqdmGuIH3vdpBpd2yxZ4mgZZQhOSC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCqYXXtZZRwgHmuaX6t[Y9{cW5ic4ThbY5qdmdiYnHz[YQhdWmlcn;zZ49xcWNibXX0bI9l MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl6MUGxN{c,OzB7OEGxNVM9N2F-
HCT116 M1X4OmFxd3C2b4TpZ{Bie3OjeR?= NIjVd|cyKHWP NIDmPFQzPCCqcoO= MUPJcoR2[3Srb36gc4Yh[XCxcITveIlkKG2xcoDoc4xw\2mlYXygZ4hidmenIHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCob4LtZZRqd25ib3[geY5{fHK3Y4T1doVlKHO2YYTlJIF1KDFidV2gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliaHHlcYF1d3i7bHnuMYVwe2mwIIP0ZYlvcW6pIHLhd4VlKG2rY4Lvd4NweGmlIH3leIhw\A>? NH7m[lM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4NVEyOyd-M{C5PFEyOTN:L3G+
HCT116 MYPBdI9xfG:2aXOgZZN{[Xl? MUixJJVO MlnUNlQhcHK| NUDHfG5ZUW6mdXP0bY9vKG:oIHHwc5B1d3SrYzDtc5JxcG:ub3fpZ4FtKGOqYX7n[UBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOg[o9zdWG2aX;uJI9nKH[xbIXt[UB{f2WubHnu[{BifCBzIIXNJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHjh[Y1ifG:6eXzpck1md3OrbjDzeIFqdmmwZzDiZZNm\CCvaXPyc5Nkd3CrYzDt[ZRpd2R? NFLlSoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4NVEyOyd-M{C5PFEyOTN:L3G+
HCT116 NEXKUWdCeG:ydH;0bYMh[XO|YYm= M37qdlEhfU1? MUKyOEBpenN? MlfOTY5lfWO2aX;uJI9nKGGyb4D0c5Rq[yCvb4LwbI9td2erY3HsJINp[W6pZTDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiZn;ycYF1cW:wIH;mJINwdmSnboPl[EBvfWOuZXmgZZQhOSC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCqYXXtZZRwgHmuaX6t[Y9{cW5ic4ThbY5qdmdiYnHz[YQhdWmlcn;zZ49xcWNibXX0bI9l NVHkfHBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFEyOTNpPkOwPVgyOTF|PD;hQi=>
HCT116 NEnYVFRCeG:ydH;0bYMh[XO|YYm= NXXabWxpOSC3TR?= M3vxSVI1KGi{cx?= M{nsPWlv\HWldHnvckBw\iCjcH;weI91cWNibX;ydIhwdG:paXPhcEBkcGGwZ3WgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhdHm|aYOgZZQhOSC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCqYXXtZZRwgHmuaX6t[Y9{cW5ic4ThbY5qdmdiYnHz[YQhdWmlcn;zZ49xcWNibXX0bI9l NIXy[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4NVEyOyd-M{C5PFEyOTN:L3G+
HCT116 MV3BdI9xfG:2aXOgZZN{[Xl? NF;rUJAyKHWP NEPQ[5EzPCCqcoO= NWPt[oNMUW6mdXP0bY9vKG:oIHHwc5B1d3SrYzDtc5JxcG:ub3fpZ4FtKGOqYX7n[UBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgcYVu[nKjbnWgd4hzcW6tYXflJIF1KDFidV2gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliaHHlcYF1d3i7bHnuMYVwe2mwIIP0ZYlvcW6pIHLhd4VlKG2rY4Lvd4NweGmlIH3leIhw\A>? NGPWO2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4NVEyOyd-M{C5PFEyOTN:L3G+
PLC/PRF/5 MX3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3vWeFczKGi{cx?= MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCOQz;QVmYwPSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGOnbHzzMEBKSzVyPUeuOFHPxE1? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTJyMEKzPEc,OzF{MECyN|g9N2F-
HepG2 MnfBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MljVO|IhcHK| MonrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFQ1u4JINmdGy|LDDJR|UxRThwMUNOwG0> NET3Z5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNFI{QCd-M{GyNFAzOzh:L3G+
RPMI8226 MknRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MVW3NkBpenN? NVHIVpo6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSVG1KQDJ{NjDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHPlcIx{NCCLQ{WwQVkvOjYQvF2= NF3Y[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNFI{QCd-M{GyNFAzOzh:L3G+
LO2 NXP4NXFmS3m2b4TvfIlkcXS7IHHzd4F6 NHHST4c4OiCqcoO= MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMU|Ih[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliQ1PLPEBk\WyuczygTWM2OD1zNz60O:69VQ>? NWfhdWFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyNFAzOzhpPkOxNlAxOjN6PD;hQi=>
A549 NF:xcllCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NXfZcWluPzJiaILz M4PieWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFQ1u4JINmdGy|LDDJR|UxRTNyLkVOwG0> M{fmO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMkCwNlM5Lz5|MUKwNFI{QDxxYU6=
HepG2 NFfKZ|VHfW6ldHnvckBie3OjeR?= M1fGdlAvOSC2bzCxJJVO NI\NUWMyOCCmYYnz M3y0XGlvcGmkaYTpc44hd2ZiY3;sc456KG[xcn3heIlwdiCrbjDoeY1idiCKZYDHNkBk\WyuczDheEAxNjFidH:gNUB2VSCrbnP1ZoF1\WRiZn;yJFExKGSjeYOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnegZoF{\WRibXnjdo9{[2:yaXOgcYV1cG:m M3HoVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMkCwNlM5Lz5|MUKwNFI{QDxxYU6=
PLC/PRF/5 M1;uWGZ2dmO2aX;uJIF{e2G7 NGDUSVAxNjByMTD0c{AyKHWP NFn1dpQyOCCmYYnz NGj5c49KdmirYnn0bY9vKG:oIHPvcI9vgSCob4LtZZRqd25iaX6gbJVu[W5iUFzDM3BTTi93IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJINwdG:weTDzbZpmKGG2IECuNFAyKHSxIEGgeW0hcW6ldXLheIVlKG[xcjCxNEBl[Xm|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pIHLhd4VlKG2rY4Lvd4NweGmlIH3leIhw\A>? NELxdnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUKwNFI{QCd-M{GyNFAzOzh:L3G+
K562 MoDDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NYjyRY9qPzJiaILz NX7LfWtCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQvPzoQvF2= M13YTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMkCyPVkzLz5|MUKwNlk6OjxxYU6=
SGC7901 NEPEV3lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MoDtO|IhcHK| MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOJQ{e5NFEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{45P87:TR?= M2fz[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMkCyPVkzLz5|MUKwNlk6OjxxYU6=
Bel7402 MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M2nYVVczKGi{cx?= NH;3PIVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLlcFc1ODJiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:QC5|Md88US=> M4TldlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMkCyPVkzLz5|MUKwNlk6OjxxYU6=
A549 NH;TTnNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NFfxOHQ4OiCqcoO= NFzxN5dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVcvQM7:TR?= MmO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF{MEK5PVIoRjNzMkCyPVkzRC:jPh?=
L02 M2qwe2N6fG:2b4jpZ4l1gSCjc4PhfS=> NGLEWG04OiCqcoO= MlT3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUFAzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE5NjZ6zszN MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTJyMkm5Nkc,OzF{MEK5PVI9N2F-
TE1 M4GyT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MUe3NkBpenN? MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFSHMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTF{Lkez{txO NFziUZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUS5OFQ4Oid-M{G0PVQ1PzJ:L3G+
A549 NVXWblhWSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MliwO|IhcHK| NUXRWIF3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NVMvPDYQvF2= M4f4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNEm0OFczLz5|MUS5OFQ4OjxxYU6=
MGC803 NET4XJZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{\N[|czKGi{cx?= NVSyZWNoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2M5ODNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0yPC5zM988US=> Mn7RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF2OUS0O|IoRjNzNEm0OFczRC:jPh?=
MCF7 MX;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{LHUFczKGi{cx?= NHjvW2FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2yNU46P87:TR?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTR7NES3Nkc,OzF2OUS0O|I9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
BCR-ABL / Myc ; 

PubMed: 28128329     


Immunoblotting showing the effect of 2-hour of oridonin treatment on the expression of chaperons.

p-AMPK / AMPK / Glut1 / LC3 ; 

PubMed: 28230866     


Detection of these proteins in a time course experiment after oridonin treatment. Oridonin downregulated p-AMPK and GLUT1 in a time-dependent manner in SW480 cells. 

28128329 28230866
Immunofluorescence
HSF1; 

PubMed: 28128329     


Immunofluorescence detecting HSF1 (Red) in Ph+ leukemia cells. Cells were treated with DMSO or oridonin (K562: 20 μM; KU812 and SUP-B15: 10 μM) for 24 hours, immuno-stained and analyzed by confocal microscopy. 

p65; 

PubMed: 25886043     


NB4 cells were treated with 10 μM oridonin for the indicated times. The intracellular localization of p65 was analyzed by indirect immunofluorescence using anti-p65 antibodies (green). Nuclear DAPI staining (blue) is also shown. Scale bars represent 20 μm. 

28128329 25886043
Growth inhibition assay
Cell viability; 

PubMed: 26496199     


Effects of oridonin on the viability of KYSE-150 cells.

26496199
In vivo

LD50: Mice 35-40mg/kg. [4]

Protocol

Solubility (25°C)

In vitro DMSO 72 mg/mL (197.56 mM)
Ethanol 28 mg/mL (76.83 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+20%PEG 300+ddH2O
For best results, use promptly after mixing.
12.5mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.43
Formula

C20H28O6

CAS No. 28957-04-2
Storage powder
in solvent
Synonyms Isodonol, Rubescenin
Smiles CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Related Akt Products

Tags: buy Oridonin (NSC-250682) | Oridonin (NSC-250682) supplier | purchase Oridonin (NSC-250682) | Oridonin (NSC-250682) cost | Oridonin (NSC-250682) manufacturer | order Oridonin (NSC-250682) | Oridonin (NSC-250682) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID